Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

被引：3

作者：

Los Arcos, Marta Barrado ^{[1
,2
]}

Lopez-Campos, Fernando ^{[3
]}

Valcarcel, Marta Lopez ^{[4
]}

Rubio, Manuel Galdeano ^{[5
]}

de Manzanos, Ignacio Visus Fernandez ^{[1
,2
]}

Duque-Santana, Victor ^{[3
]}

Aparicio, Marian Gomez ^{[6
]}

Martin, Juan Zafra ^{[7
,8
]}

Kishan, Amar U. ^{[9
,10
]}

Achard, Verane ^{[11
,12
]}

Siva, Shankar ^{[13
,14
]}

Counago, Felipe ^{[15
]}

机构：

[1] Hosp Univ Navarra, Pamplona, Navarra, Spain

[2] Inst Invest Navarra IdiSNA, Pamplona, Navarra, Spain

[3] Hosp Univ Ramon y Cajal, Madrid, Spain

[4] Hosp Univ Puerta Hierro, Madrid, Spain

[5] Hosp Terrassa Consorci Sanitari Terrassa, Terrassa, Cataluna, Spain

[6] Hosp Gen Univ Toledo, Toledo, Spain

[7] Hosp Univ Virgen Victoria, Malaga, Spain

[8] Univ Granada, Granada, Spain

[9] Univ Calif Los Angeles, Los Angeles, CA USA

[10] UCLA, Dept Radiat Oncol, Los Angeles, CA USA

[11] Hop Fribourgeois HFR Freiburger Spital HFR, Fribourg, Switzerland

[12] HUG Hop Univ Geneve, Geneva, Switzerland

[13] Peter Maallum Canc Ctr, Melbourne, Australia

[14] Univ Melbourne, Melbourne, Australia

[15] Genesis Care, La Milagrosa Hosp, San Francisco de Asis Hosp, Natl Chair Res & Clin Trials, Madrid, Spain

来源：

CLINICAL GENITOURINARY CANCER | 2023年 / 21卷 / 03期

关键词：

Metastasis-directed therapy; Metastatic prostate cancer; Radiotherapy; METASTASIS-DIRECTED THERAPY; PHASE-II TRIAL; BODY RADIOTHERAPY; MULTICENTER; RECURRENCE; SURVEILLANCE; PROGRESSION; STOMP;

D O I：

10.1016/j.clgc.2022.10.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antian-drogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in differ-ent tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.

引用

页码：E93 / E103

页数：11

共 50 条

[31] Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
Mueller, Arndt-Christian
Aebersold, Daniel M.
Albrecht, Clemens
Boehmer, Dirk
Flentje, Michael
Ganswindt, Ute
Ghadjar, Pirus
Schmidt-Hegemann, Nina-Sophie
Hoecht, Stefan
Hoelscher, Tobias
Niehoff, Peter
Pinkawa, Michael
Sedlmayer, Felix
Wolf, Frank
Zamboglou, Constantinos
Zips, Daniel
Wiegel, Thomas
STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (08) : 683 - 689
[32] Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
Arndt-Christian Müller
Daniel M. Aebersold
Clemens Albrecht
Dirk Böhmer
Michael Flentje
Ute Ganswindt
Pirus Ghadjar
Nina-Sophie Schmidt-Hegemann
Stefan Höcht
Tobias Hölscher
Peter Niehoff
Michael Pinkawa
Felix Sedlmayer
Frank Wolf
Constantinos Zamboglou
Daniel Zips
Thomas Wiegel
Strahlentherapie und Onkologie, 2022, 198 : 683 - 689
[33] Rezvilutamide for metastatic hormone-sensitive prostate cancer
Ye, Dingwei
Gu, Weijie
Li, Junliang
LANCET ONCOLOGY, 2022, 23 (11): : E491 - E491
[34] Treatment of metastatic hormone-sensitive prostate cancer
Rane, Jayant K.
Chowdhury, Amani
Kinnaird, William
Marks, Gillian
Davda, Reena
TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
[35] Management of Metastatic Hormone-Sensitive Prostate Cancer
Bernard, Brandon
Sweeney, Christopher J.
CURRENT UROLOGY REPORTS, 2015, 16 (03)
[36] Management of Metastatic Hormone-Sensitive Prostate Cancer
Brandon Bernard
Christopher J. Sweeney
Current Urology Reports, 2015, 16
[37] Docetaxel for hormone-sensitive metastatic prostate cancer
Baker, Holly
LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
[38] Management of Hormone-Sensitive Metastatic Prostate Cancer
Agarwal, Neeraj
Hussain, Maha
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (06) : 1221 - +
[39] Update on Metastatic Hormone-Sensitive Prostate Cancer
Chi, Kim N.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 277 - 280
[40] Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
Baron, D.
Pasquier, D.
Pace-Loscos, T.
Vandendorpe, B.
Schiappa, R.
Ortholan, C.
Hannoun-Levi, J. M.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 43

← 1 2 3 4 5 →